About Solis Tek
Solis Tek is a provider in the hydroponic industry for digital lighting. All gardens need light and Solis Tek is one company that keeps setting new standards for product quality and customer convenience. The Solis Tek product line features digital ballast with innovative features and lamps exclusively developed by a highly accredited NASA advisor along with reflectors and other accessories to complete every gardens ideal lighting system. Solis Tek has also recently formed a strategic partnership with a local china factory to obtain the lowest costs out of any current competitor for digital ballasts. Solis Tek is striving to take over majority market share for the hydroponics industry while begin to penetrate more into the commercial market as well as the European hydroponics market.
Latest Solis Tek News
Sep 14, 2018
G Farma, Solis Tek, and GB Sciences Increase Mentor’s Marijuana Holdings September 14, 2018 08:05 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--Mentor Capital, Inc. (OTCQX: MNTR) announced that its investment in G FarmaLabs Limited has increased to $2,700,000 following yesterday’s seventh investment tranche delivered to G Farma of $250,000 from Mentor for additional leased equipment and working capital. In addition to receiving consulting fees, repayment, interest, and lease payments, Mentor has captured a $1 option for a 3.75% equity interest in the G Farma Family of Businesses. Nicole Gonzalez, Founder of G FarmaBrands, comments, “With financial backing from Mentor Capital, G FarmaLabs has hit its benchmarks on the way to building cannabis efficient facilities and production lines.” Ata Gonzalez, Co-Founder of G FarmaLabs concludes, “Chet provides both money and a wealth of knowledge. We feel blessed to have this strategic relationship.” “Mentor Capital focuses new investment from shareholders and other investors on larger cannabis companies, like G Farma, that have the potential to go public and who may be incubated by Mentor along that path,” explained Mentor Capital, Inc. CEO, Chet Billingsley. “We look to act as a holding company of operating entities, not an investment company, and have no plans to buy cannabis shares from the public market at normal market prices. However, on 24-hour notice and hence at a significant discount, Mentor will buy public shares from marijuana-related consultants, institutions, or accredited investors that Mentor has known for years.” The Company reports that in the last two months, Mentor has increased its holding in SolisTek to 300,000 shares by the purchase of an additional 90,000 common shares. Mentor recently has purchased 400,000 shares of GB Sciences, Inc. plus an extra 400,000 of their warrants. Mentor also holds from earlier buying activity approximately a combined $240,000 in shares of GW Pharmaceuticals, Plc. and Kush Bottles, Inc. About Mentor Capital: The Company seeks to come alongside and assist private medical marijuana and cannabis companies and their founders in meeting their liquidity and financial objectives, to add protection for investors and to help incubate larger private cannabis companies. Additional important information for investors is presented at: This press release is neither an offer to sell nor a solicitation of offers to purchase securities. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal securities laws, including statements concerning financial projections, financing activities, corporate combinations, product development activities and sales and licensing activities. Such forward-looking statements are not guarantees of future results or performance, are sometimes identified by words of condition such as “should,” “could,” “expects,” “may,” “intends,” “seeks,” “looks,” “moves,” or “plans” and are subject to a number of risks and uncertainties, known and unknown, that could cause actual results to differ materially from those intended or anticipated. Such risks include, without limitation: nonperformance of investments, partner and portfolio difficulties, potential delays in marketing and sales, problems securing the necessary financing to continue operations, problems involving continued illegality of cannabis products, potential of competitive products, services, and technologies, difficulties experienced in product development, in recruiting knowledgeable personnel and in protecting intellectual property. Further information concerning these, and other risks is included in the Company’s Form 10-K filing which, along with other very important information about the Company, can be found here:
Solis Tek Frequently Asked Questions (FAQ)
Where is Solis Tek's headquarters?
Solis Tek's headquarters is located at 16926 South Keegan Avenue, Carson.
What is Solis Tek's latest funding round?
Solis Tek's latest funding round is IPO.